We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01590225
Recruitment Status : Withdrawn
First Posted : May 2, 2012
Last Update Posted : January 29, 2021
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme LLC

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a three-part (Part A, Part B, and Part C), open-label, multicenter study of boceprevir in pediatric participants with chronic hepatitis C (CHC) genotype 1 (GT1). In Part A and Part B, efficacy and safety will be evaluated in participants with CHC GT1 who are non-cirrhotic, treatment naïves (Part A) or who are non-cirrhotic, treatment failures to (peg)interferon/ribavirin or who are cirrhotics (whether treatment naïve or treatment failure) (Part B). Part C is long-term follow up and no study treatment will be administered during this period, but participants who do not achieve viral clearance will be allowed to receive other treatments for CHC.

Condition or disease Intervention/treatment Phase
Chronic Hepatitis C Drug: Boceprevir Drug: Peginterferon alpha-2b Drug: Ribavirin Drug: Peginterferon alfa-2b Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1
Actual Study Start Date : January 28, 2013
Estimated Primary Completion Date : August 18, 2021
Estimated Study Completion Date : August 18, 2021

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Part A: boceprevir + peginterferon alpha-2b + ribavirin Drug: Boceprevir
Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for 24 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
Other Names:
  • Victrelis®
  • SCH 503034

Drug: Peginterferon alpha-2b
Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m^2 once weekly (QW) for 24 weeks.
Other Names:
  • Pegintron®
  • Sylatron®

Drug: Ribavirin
The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily [BID]) for 24 weeks.
Other Names:
  • Copegus®
  • Rebetol®
  • RibaTab®
  • Ribasphere®
Experimental: Part B: boceprevir + peginterferon alpha-2b + ribavirin Drug: Boceprevir
Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for up to 48 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.

Drug: Peginterferon alfa-2b
Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m^2 once weekly (QW) for 48 weeks.
Other Names:
  • Pegintron®
  • Sylatron®

Drug: Ribavirin

Drug: Ribavirin

The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily [BID]) for 48 weeks.

Other Names:
  • Copegus®
  • Rebetol®
  • RibaTab®
  • Ribasphere®


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Participants Achieving Sustained Viral Response (SVR) at Follow-Up Week 24 in Study Part A [ Time Frame: Follow-Up Week 24 ]
  2. Participants Achieving SVR at Follow-Up Week 24 in Study Part B [ Time Frame: Follow-Up Week 24 ]
  3. Time to Viral Relapse in Study Part C [ Time Frame: Follow-Up Week 24 to 5 Years ]

Secondary Outcome Measures :
  1. Proportion of Participants With Alanine Aminotransferase (ALT) Normalization in Study Part A [ Time Frame: Week 2, Week 4, Week 8, Week 12 ]
  2. Participants With Early Virologic Response in Study Part A [ Time Frame: Week 2, Week 4, Week 8, Week 12 ]
  3. Proportion of Participants With Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA) in Study Part A [ Time Frame: Week 12, End of Treatment, Follow-Up Week 24 ]
  4. Proportion of Participants With Undetectable HCV-RNA Who Also Achieved SVR in Study Part A [ Time Frame: Follow-Up Week 12 ]
  5. Proportion of Participants With Alanine Aminotransferase (ALT) Normalization in Study Part B [ Time Frame: Week 2, Week 4, Week 8, Week 12 ]
  6. Proportion of Participants With Undetectable HCV-RNA in Study Part B [ Time Frame: Week 24, End of Treatment, Follow-Up Week 12 ]
  7. Proportion of Participants With Undetectable HCV-RNA Who Also Achieved SVR in Study Part B [ Time Frame: Follow-Up Week 12 ]
  8. Number of Participants Experiencing Treatment-Emergent Adverse Events (AEs) in Study Part A [ Time Frame: Week 1 to Follow-Up Visit 24 ]
  9. Number of Participants Experiencing Treatment-Emergent Treatment-Related AEs in Study Part A [ Time Frame: Week 1 to Follow-Up Week 24 ]
  10. Number of Participants Experiencing Serious AEs (SAEs) in Study Part A [ Time Frame: Week 1 to Follow-Up Week 24 ]
  11. Participants Discontinuing Treatment Due to AEs in Study Part A [ Time Frame: Week 1 to Follow-Up Week 24 ]
  12. Change from Baseline in Participant Laboratory Values in Study Part A [ Time Frame: Baseline to Follow-Up Week 24 ]
  13. Change From Baseline in Participant Vital Signs in Study Part A [ Time Frame: Baseline to Follow-Up Week 24 ]
  14. Number of Participants Experiencing AEs in Study Part B [ Time Frame: Week 1 to Follow-Up Week 24 ]
  15. Number of Participants Experiencing SAEs in Study Part B [ Time Frame: Week 1 to Follow-Up Week 24 ]
  16. Change from Baseline in Participant Laboratory Values in Study Part B [ Time Frame: Week 1 to Follow-Up Week 24 ]
  17. Change From Baseline in Participant Vital Signs in Study Part B [ Time Frame: Week 1 to Follow-Up Week 24 ]
  18. Number of Participants Discontinuing From Study Treatment Due to AEs in Study Part B [ Time Frame: Week 1 to Follow-Up Week 24 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • CHC GT1 infection for at least 6 months with with HCV-RNA ≥10,000 IU/mL.
  • Treatment naive, non-cirrhotic participants will be eligible for inclusion in Study Part A
  • Non-cirrhotic subjects who failed previous (peg)interferon/ribavirin treatment for CHC and cirrhotics, whether treatment naive or treatment failure, will be eligible for inclusion in Study Part B
  • To participate in Study Part C, participants must have completed the required post-treatment follow-up in Study Part A or Part B
  • Weight ≥ 10 kg to ≤ 125 kg
  • Body surface area (BSA) ≥0.46 m^2 and ≤2.5 m^2
  • Previous liver biopsy with histology consistent with chronic hepatitis C and no other etiology within 2 years of the screening visit
  • Participants with bridging fibrosis or cirrhosis must have an ultrasound within 6 months of the screening visit or between the screening visit and Day 1 with no findings suspicious for hepatocellular carcinoma
  • Participant must be able to adhere to dose and visit schedules

Exclusion Criteria:

  • Known co-infection with the the human immunodeficiency virus (HIV) or hepatitis B virus (HBsAg positive)
  • For Study Part A, participant received any prior hepatitis C treatment, including herbal remedies, with known hepatotoxicity
  • For Study Part B, participant received treatment with ribavirin within 90 days or any interferon alpha within 30 days prior to screening
  • For Study Part B, participant received previous treatment with a hepatitis C virus protease inhibitor (excepting participants in study P07614, Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1)
  • For Study Part B, participant required discontinuation of previous (peg)interferon/ribavirin therapy for an adverse event considered by the investigator to be related to (peg)interferon and/or ribavirin
  • For Study Part B, participant is currently taking any antiviral/immunomodulatory treatment for hepatitis C
  • Participant has taken any investigational drugs, except boceprevir
  • Participant has received any of the following medication(s) within 2 weeks prior to the Day 1 visit: midazolam, pimozide, amiodarone, flecainide,

propafenone, quinidine, and ergot derivatives (dihydroergotamine, ergonovine,

ergotamine, methylergonovine)

  • Participation in any other clinical trial within 30 days of enrollment or

intent to participate in another clinical trial during participation in the current study

  • Evidence of decompensated liver disease
  • Child Pugh score >6 (class B and C)
  • History of diabetes or hypertension or was born prior to 32 weeks

of gestation and has clinically significant ocular examination findings

  • Pre-existing clinically significant psychiatric condition(s)
  • Clinical diagnosis of substance abuse
  • Any pre-existing medical condition that could interfere with participation in and completion of the study
  • Evidence of active or suspected malignancy
  • Females who are pregnant, nursing, or intend to become pregnant during

the study period

  • Allergy or sensitivity to the investigational products or excipients
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

No Contacts or Locations Provided
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Merck Sharp & Dohme LLC
ClinicalTrials.gov Identifier: NCT01590225    
Other Study ID Numbers: P08034
2010-024260-17 ( EudraCT Number )
First Posted: May 2, 2012    Key Record Dates
Last Update Posted: January 29, 2021
Last Verified: January 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis
Hepatitis, Chronic
Hepatitis, Viral, Human
Liver Diseases
Digestive System Diseases
Virus Diseases
Infections
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
 Blood-Borne Infections
Communicable Diseases
Flaviviridae Infections
Ribavirin
Peginterferon alfa-2b
Interferon-alpha
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs